Neurodegenerative Disorders and the Gut-Microbiome-Brain Axis: A Literature Review
Open Access
- 26 October 2024
- journal article
- Published by Springer Nature in Cureus
- Vol. 16 (10)
Abstract
Neurodegenerative diseases are severe, age-related conditions with complex etiologies that result in significant morbidity and mortality. The gut microbiome, a dynamic symbiotic environment comprising commensal organisms, represents the largest reservoir of these organisms within the human body. It produces short-chain fatty acids, endogenous signals, and neuroactive compounds, which can modulate neuronal function, plasticity, and behavior. Emerging evidence suggests that the gut microbiome plays a pivotal role in neurodevelopment, aging, and brain diseases, including Alzheimer’s disease, Parkinson’s disease, and stroke. Communication between the gut and brain occurs through a bidirectional channel known as the gut-microbiome-brain axis, which is being explored for therapeutic potential in neurodegenerative disorders. This literature review was conducted through a comprehensive search of five electronic databases - PubMed, Scopus, Ovid Medline, Cochrane Review, and Google Scholar - from inception to June 2024, focusing on English-language studies. Keywords included “gut-brain axis”, “microbiome dysbiosis”, “neurodegeneration”, and disorder-specific terms such as “Alzheimer’s disease” and “Parkinson’s disease”, paired with “gut microbiome”. The review examines current knowledge on the relationship between gut microbiota and neurodegenerative disorders, emphasizing potential mechanisms and therapeutic options. Results indicate that gut dysbiosis, characterized by microbial imbalance, is intricately associated with neurodegenerative disease pathogenesis by influencing immune responses, increasing blood-brain barrier permeability, and generating neurotoxic metabolites. Therapeutic approaches targeting the gut microbiome, including probiotics, prebiotics, and fecal microbiota transplantation, show promise in restoring microbial balance and slowing disease progression. However, further research is essential to validate these findings and develop effective clinical interventions.Keywords
This publication has 51 references indexed in Scilit:
- Fecal microbiota transplant as a potential treatment for Parkinson's disease – A case seriesClinical Neurology and Neurosurgery, 2021
- Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington's diseaseNeurobiology of Disease, 2020
- Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trialClinical Nutrition, 2019
- RETRACTED: Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trialClinical Nutrition, 2019
- The Dynamics of the Gut Microbiome in Multiple Sclerosis in Relation to DiseaseNeurologic Clinics, 2018
- Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderlyNeurobiology of Aging, 2017
- Human gut microbiota: the links with dementia developmentProtein & Cell, 2016
- Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?European Neuropsychopharmacology, 2015
- Gut Microbiome and Multiple SclerosisCurrent Neurology and Neuroscience Reports, 2014
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993